Is the Eupraxia Pharmaceuticals (EPRX) investment thesis intact?

Yes. Readouts currently rates the Eupraxia Pharmaceuticals Thesis Intact. RESOLVE reaches enrollment target ahead of December Phase 2b interim data.

What is the next catalyst for Eupraxia Pharmaceuticals (EPRX)?

The next dated event is Phase 2b topline results (RESOLVE) for EP-104GI, expected December 2026, as stated by the company.

How long will Eupraxia Pharmaceuticals' cash last?

Eupraxia Pharmaceuticals has said its cash will fund operations into the second half of 2028 (guidance as of August 11, 2026).

EPRXEupraxia Pharmaceuticals Inc.

IntactLast material event May 12, 2026 · Updated Oct 15, 2026

RESOLVE reaches enrollment target ahead of December Phase 2b interim data

Eupraxia Pharmaceuticals is a clinical-stage company developing EP-104GI, a long-acting steroid injected into the wall of the esophagus for eosinophilic esophagitis (EoE); it is not approved.

Eupraxia's case rests on EP-104GI delivering durable EoE control through a single administration into the esophageal wall. Open-label RESOLVE results support that potential: 9 of 14 patients remained in clinical remission at 52 weeks. The randomized Phase 2b has reached its enrollment target, with December 2026 interim data expected on symptoms, histology and safety. Those controlled results remain the key investment decision; management guides to a runway extending well into 2028.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

EP-104GI beats placebo in the randomized Phase 2bAwaiting evidenceDecember 2026 interim symptom, histology and safety results by dose versus vehicle control.Next: December 2026 interim symptom, histology and safety results by dose versus vehicle control.

Why it is in this state

The evidence, what would weaken it and the source filing

Single-dose remission lasts a yearSupportedRandomized durability findings, including patients reaching 9- and 12-month follow-up in the interim analysis.Next: Randomized durability findings, including patients reaching 9- and 12-month follow-up in the interim analysis.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash covers the Phase 2b and Phase 3 preparationSupportedNext financial results: cash plus short-term investments and operating cash use relative to development plans.Next: Next financial results: cash plus short-term investments and operating cash use relative to development plans.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

RESOLVE Phase 2b interim results versus placebo

Tests: EP-104GI beats placebo in the randomized Phase 2b

December 2026 (company guidance)

Does EP-104GI improve symptoms and histology versus placebo with acceptable safety?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentFinancial

+2.6%May 12, 2026

RESOLVE reaches enrollment target ahead of December Phase 2b interim data

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Eosinophilic esophagitis

EP-104GI · 3 upcoming · 1 completed

Phase 2b Data: ToplineRESOLVE

Dec 2026

Phase 1b/2 Data: UpdateRESOLVE

TBD

Phase 3 Study Initiation

TBD

Knee osteoarthritis pain

EP-104IAR · 1 completed

Phase 2b Data: ToplineSPRINGBOARD

Reported Apr 24, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Eupraxia Pharmaceuticals (EPRX) investment thesis intact?: Yes. Readouts currently rates the Eupraxia Pharmaceuticals Thesis Intact. RESOLVE reaches enrollment target ahead of December Phase 2b interim data.
What is the next catalyst for Eupraxia Pharmaceuticals (EPRX)?: The next dated event is Phase 2b topline results (RESOLVE) for EP-104GI, expected December 2026, as stated by the company.
How long will Eupraxia Pharmaceuticals' cash last?: Eupraxia Pharmaceuticals has said its cash will fund operations into the second half of 2028 (guidance as of August 11, 2026).

Disease areas: Neurology and pain, Liver and digestive diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

2 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.